A Comparative Clinical Study of Latanoprost and Isopropyl Unoprostone in Japanese Patients with Primary Open-Angle Glaucoma and Ocular Hypertension
A Comparative Clinical Study of Latanoprost and Isopropyl Unoprostone in Japanese Patients with Primary Open-Angle Glaucoma and Ocular Hypertension
复制标题
拉坦前列素与异丙基乌诺前列酮治疗日本原发性开角型青光眼并高眼压症患者的临床对比研究
作者：
H. Tsukamoto;H. Mishima;Y. Kitazawa;M. Araie;H. Abe;A. Negi
PurposeTo compare the efficacy and safety of latanoprost versus isopropyl unoprostone (unoprostone) in Japanese patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH). MethodsAn 8-week, multicenter, randomized, comparative study was performed in 48 Japanese patients with POAG or OH. Four patients (two in each group) withdrew from the study, but their data were included in the safety assessment but not in the intraocular pressure (IOP) evaluation. The patients were randomly treated with latanoprost 0.005% once daily or unoprostone 0.12% twice daily for 8 weeks. IOP was measured at baseline and 2, 4, and 8 weeks after treatment. In addition, ocular and systemic adverse events were recorded. ResultsThe baseline IOPs were similar between the latanoprost (n = 25) and unoprostone (n = 19) groups (24.3 ± 2.4 mm Hg vs 23.3 ± 2.1 mm Hg, respectively, P = 0.18). The IOP reductions from baseline at 2, 4, and 8 weeks after treatment were 5.8 ± 2.4, 6.6 ± 2.5, and 6.7 ± 2.0 mm Hg in the latanoprost group, and 3.8 ± 2.0, 3.5 ± 2.3, and 3.3 ± 3.0 mm Hg in the unoprostone group, respectively. The IOP reduction in the latanoprost group at 8 weeks was larger than that in the unoprostone group (P < 0.001, analysis of covariance). Five adverse events were observed in 4 (15%) of 27 patients in the latanoprost group, and five adverse events were observed in 4 (20%) of 21 patients in the unoprostone group. There was no difference in the incidence of adverse events between groups (P = 0.71). ConclusionLatanoprost produced a statistically greater reduction in IOP than unoprostone in Japanese patients with POAG or OH.
登录
查看更多内容
影响因子：
5.1
作者：
C. Toris;C. Camras;M. Yablonski;R. Brubaker
通讯作者：
C. Toris;C. Camras;M. Yablonski;R. Brubaker
影响因子：
13.7
作者：
C. Toris;C. Camras;M. Yablonski
通讯作者：
C. Toris;C. Camras;M. Yablonski
Bunazosin 通过增加葡萄膜巩膜流出来降低兔子的眼内压。
DOI：
10.1089/jop.1998.14.217
发表时间：
1998
期刊：
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
影响因子：
--
作者：
Zhan,GL;Toris,CB;Camras,CB;Wang,YL;Yablonski,ME
通讯作者：
Yablonski,ME
人类受试者中肾上腺素和噻吗洛尔的荧光光度研究。
DOI：
10.1001/archopht.1981.03930020086007
发表时间：
1981
期刊：
Archives of ophthalmology (Chicago, Ill. : 1960)
影响因子：
--
作者：
Schenker,HI;Yablonski,ME;Podos,SM;Linder,L
通讯作者：
Linder,L